The terminology of AML with myelodysplasia related changes (AML-MRC) is replaced by AML, myelodysplasia-related (AML-MR) in WHO-HAEM5, representing a single entity defined by the presence of at least one of the following: history of MDS or MDS/MPN, MR cytogenetic abnormalities and/or MR gene mutations (Table 7). This evidence concerns the gene NR3C2 and myelodysplastic syndrome.